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Abstract: A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to 
infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the implication 
of this haplotype in the response to infliximab in a larger cohort of Caucasian patients. The response to the first 
infusion with infliximab was evaluated in 214 Caucasian patients with either luminal (n= 150) or fistulising (n = 
64) CD. Clinical response was based on the decrease in CD Activity Index (luminal) or on the evolution in the 
fistula discharge (fistulising). Biological response was assessed in 139 patients who had elevated C-reactive 
protein (CRP) before treatment and for whom CRP values were also available after treatment. A positive 
biological response was defined as a decrease in CRP of at least 25%. The patients were genotyped for six 
polymorphisms in the LTA gene. A positive clinical response was present in 65.4% of the patients and a positive 
biological response was observed in 80.6% of the patients. No association was found with any of the studied 
polymorphisms, nor with the previously published LTA haplotype and the response to infliximab. We could not 
confirm an association between the LTA locus and clinical or biological response to infliximab in a large cohort 
of CD patients.  
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Introduction 
Infliximab, an anti-tumor necrosis factor-alpha (TNF) antibody, has a high therapeutic efficacy in refractory 
Crohn's disease (CD) [1], leading to a fast and considerable improvement of quality of life, and to a rapid 
improvement of the intestinal lesions as assessed by endoscopic and histological analysis [2]. After a single 
infusion, 60-80% of the patients improve their clinical condition and 33% of the patients are in clinical remission 
[3]. Therapeutic response seems to be partially determined by genetic factors. Considering the cost and potential 
side-effects of this drug a genetic targeting of the responding patients is certainly of great interest [4]. 
Several findings indicate a potential role of the lymphotoxin alpha (LTA) gene as a genetic marker for the 
response to infliximab. The LTA gene is located in the major histocompatibility complex (MHC) locus on 
chromosome 6p21 which is implicated in CD susceptibility (IBD3) [5]. Furthermore the MHC complex might 
include genetic determinants of response to infliximab in rheumatoid arthritis patients [6]. Taylor et αl. [7] have 
described a significant association between a haplotype in the LTA region and the response to this anti-TNF 
antibody in CD patients. In their study, patients carrying the LTA 1_1_1_1 haplotype (corresponding to Nco1-
TNFc-aal3-aa26) did not show any response to the treatment. However, this study was performed on a relatively 
small cohort of North American patients treated with infliximab (n=59). The studied LTA haplotype comprised 
an Nco1 restriction fragment length polymorphism in intron 1 (rs909253), a microsatellite (rs5875327) also in 
intron 1 (TNFc) and two amino acid polymorphisms [aal3 (rs2857713), aa26 (rsl041981)], respectively, in exon 
2 and in exon 3. The aa26 change corresponds to a single nucleotide polymorphism (SNP) (rsl041981) in exon 3 
leading to a modification of the sixtieth amino acid of the protein. Given that there exist no independent studies 
investigating this LTA haplotype in CD with respect to response to infliximab, the present study aimed to 
confirm the association between the LTA Nco1-TNFc-aal3-aa26 haplotype and a clinical or biological response 
to infliximab in a large cohort of Caucasian patients. 
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Materials and methods 
Study population and treatment 
Two hundred and sixty-four patients with CD treated by infliximab for the first time and included in the Belgian 
Infliximab Expanded Access Program (Schering-Plough NV/SA, study 011246-1) were studied. Approval from 
the Ethic Committee was obtained in January 2004. To be included in the Expanded Access Program, patients 
had to provide their informed consent and to fulfil one of the three following criteria: (i) single or multiple 
entero-cutaneous draining fistula(s) as a complication of CD resistant to conventional treatment for at least 3 
months; (ii) moderately to severely active CD for at least 6 months, with colitis, ileitis, or ileocolitis, confirmed 
by radiography or endoscopy, and refractory or dependent on oral corticosteroid therapy ( > 8 mg/day prednisone 
equivalent); or (iii) patients refractory or intolerant to immunosuppressive agents (methotrexate, azathioprine, 6-
mercaptopurine, or cyclosporine). 
Patients with refractory luminal disease received a single infliximab infusion at week 0. For fistulising disease, 
three consecutive infusions at weeks 0, 2 and 6 were administered. Infliximab (Remicade; Centocor Inc., 
Malvern, Pennsylvania, USA) was given as an intravenous infusion of 5 mg/kg in all patients. Both luminal (n = 
150) and fistulising (n = 64) forms were scored for the response to treatment. Luminal CD patients were 
followed prospectively for 12 weeks with clinical examination, CD activity index (CDAI) calculation and C-
reactive protein (CRP) measurement at weeks 0, 4, 8 and 12. Fistulising CD patients were followed 
prospectively for 18 weeks with physical examination including fistulous track drainage and CRP measurements 
at weeks 0, 2, 6, 10, 14 and 18. 
Patient classification 
Four patients were excluded because of their ethnic group (no Caucasian) and 46 for incomplete clinical data, 
particularly insufficient data regarding the clinical response at week 4 for the luminal disease or at week 10 for 
the fistulising disease. The response to infliximab was evaluated on the basis of both clinical and biological data. 
Clinically, the patients with luminal CD were classified as responders at week 4 according to a decrease of 70 
points in CDAI from baseline in accordance with the classification used by Taylor et al. [7] and with controlled 
trials [8]. Patients were considered as complete responders at week 4 according to a decrease of the CDAI below 
150. In fistulising disease, patients were considered as responders at week 10 according to a decrease of at least 
50% of the fistula drainage at two consecutive visits [9]. 
The biological response was evaluated at week 4 for luminal disease and at week 10 for fistulising disease on the 
basis of CRP evolution. Only the patients who presented an elevated CRP before treatment (more than twice the 
upper limit of the normal range) were considered (n=139). Patients were categorized as responders after a 
decrease of at least 25% from the baseline level [10]. 
LTA genotyping 
DNA was extracted using a conventional phenol/chloroform technique. Patients were genotyped for the 
polymorphisms previously described (rs909253, rs2857713, rs5875327, rsl041981) and two other SNPs 
(rs746868, rs3093543) in the LTA gene. 
The LTA gene was amplified by polymerase chain reaction (PCR) (primers: LTA1F: 5'- CCCGTGCTTC 
GTGCTTTGG-3', LTA2R: 5'-GAGATCAGGGGTCTG GATCA-3'; annealing temperature: 65°C, 30 cycles; 
Faststart polymerase [Roche, Basel, Switzerland); MgCl2 (1.7 mΜ)]. Direct sequencing was performed using the 
same primers and the Big Dye Terminator sequencing kit v3.1 (Applied Biosystems, Foster City, California, 
USA). The TNFc microsatellite was studied by fluorescent PCR (primers: TNFIR6 5'-
GGTTTCTCTGACTGCATCT TGTCC-3', TNFIR7: 5'-FAM TCATGGGGAGAAC CTGCAGAGAA-3'; 
annealing temperature: 60°C, 30 cycles; Gold polymerase [Applied Biosystems, Applied Biosystems); MgCl2 
(1.5 mM)]. Data were treated by the Genescan software v3.7 (Applied Biosystems). The haplotypes were rebuilt 
using Phase version 2.1 software [11-12]. 
Statistical analysis 
The clinical response rates according to the different haplotypes were compared using Fisher's exact test or the 
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chi-square test when appropriate. To be in accordance with the work of Taylor et al [7], we also compared the 
frequencies of homozygous patients of the most frequent haplotypes between responders and nonresponders 
patients, using Fisher's exact test. Comparisons were also performed considering both genotypes and alleles for 
each SNP taken separately using a chi-square test or Fisher's exact test when appropriate. The threshold for 
statistical significance was lowered to α = 0.008 after Bonferroni's adjustment for multiple test analysis. The 
CRP values were normalized and the CRP level variation before and after treatment were compared. The 
biological response according to the different haplotypes and genotypes (for each SNP) were compared by 
Fisher's exact test or chi-squared. The relative reduction of the CRP between weeks 0 and 4 was calculated in 




Patient characteristics are shown in Table 1. A clinical response was observed in 65.4% and a biological 
response in 80.6% of CD patients when considering the complete cohort. Three haplotypes are preponderant and 
the LTA 1_1_1_1 haplotype accounts for 13% (27/214), as described in the previous study. The integration of 
the genotype data of the two additional SNPs (rs746868, rs3093543) did not show any new haplotypic variation 
in this region. For example, all the patients homozygous for the LTA 1_1_1_1 (rs909253_TNFc_rs2857713_ 
rsl041981) haplotype were also homozygous 1_1_2_1_1_1 (rs909253_TNFc_rs746868_rs2857713_ rsl041981_ 
rs3093543). The studied SNPs were found in our cohort at the same frequency as described in the public 
database (http://www.ncbi.nlm.nih.gov). 
We did not find any association between the LTA 1_1_1_1 haplotype or any of the other haplotypes and the 
clinical response to infliximab (Table 2). Considering the homozygous LTA 1_1_1_1 patients, we could not 
confirm the results of Taylor's study on the complete cohort (Fisher's exact test, n = 214, P = 0.215) nor on 
luminal or fistulising forms of the disease (Table 3). We also evaluated the patients homozygous for the frequent 
allele of the rs2857713 and rsl041981 SNPs as performed by Taylor's group without confirming their results. 
Considering the biological response, no significant association was found between either the proportion of 
patients with a decrease of at least 25% in CRP level or a difference in the mean relative change in CRP and the 
studied haplotypes on the complete, luminal or fistulising cohorts. Similarly, we could not demonstrate any 
association between clinical or biological response to infliximab and individual SNPs studied separately on the 
complete cohort, as well as on the luminal and fistulising CD patients. These statistical analyses were performed 
considering the frequencies of the alleles (Table 4) as well as the frequencies of the three genotypes (data not 
shown). 
Table 1.  Patients characteristics (n = 214) 
Characteristics 
Median age (interquartile range) 38 (21-55) 
Median age at diagnosis (interquartile range) 22 (11-33) 
Patients 
Sex ratio: F/M (%) 139 (65)/75 (35) 
Luminal/fistulising (%) 151  (70.8)/63 (29.2) 
Ileon (%) 31  (14.7) 
Colon (%) 62 (29.1) 
Ileo-colonic (%) 99 (46.4) 
Upper gastrointestinal involvement (%) 11  (5.1) 
Anal involvement (%) 77 (36.2) 
Crohn's Disease Index Activity (mean±SD) 241  (±97) 
Disease 
Normalized C-reactive protein (mg/dl) 
(mean±SD) 
11.9 (±17.5) 
5-Aminosalicylates (%) 52 (24.5) 
Methotrexate (%) 13 (6.2) 
Steroids (%) 59 (27.6) 
Concomitant 
treatment 
Azathioprine/6-mercaptopurine (%) 121  (56.8) 
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Table 2. Observed haplotype frequencies (%) and numbers of alleles (n) in responding and nonresponding 
patients (clinical response) 
Haplotype Nonresponders Responders P 
1_1_1_2_1_1  (n) 2.2 (3) 4.3 (11) 0.2146 
1_1_2_2_1_1  (n) 1 7.8 (24) 1 8.6 (47) 0.8072 
1_1_2_2_2_1  (n) 5.9 (8) 5.1  (13) 0.7637 
1_2_1_1_1_1  (n) 38.5 (52) 38.4 (97) 0.9604 
1_2 _2_1_1_1  (n) 1.5 (2) 2.7 (7) 0.3336 
2_1_1_1_1_2 (n) 31.8 (43) 29.6 (75) 0.7045 
2 _1_ 2_1_1_ 2 (n) 2.2 (3) 1.2 (3) 0.3533 
Total 135 253 0.3533 
The haplotypes (noted 1 for the major allele, considering, respectively, rs909253_ rs746868_ rs5875327_ rs2857713_ rs3093543_ 
rs1041981) were rebuilt with Phase software version 2.1. For each subgroup of patients (responders/nonresponders), the frequencies of the 
haplotypes and the number of alleles (n) are reported. P-values were calculated using the chi-square test or Fisher's exact test when 
appropriate, considering a total of 388 alleles. 
 
Table 3.  Polymorphisms allele frequencies and P-values considering the clinical response 
 Minor allele frequency percentage 
(number of alleles) 
P 
Microsatellite or SNP ID Disease type Nonresponders Responders Alleles 
All 28.4 (40) 28.2 (79) 0.145 
Luminal 28 (31) 29.6 (54) 0.303 
TNFc (GA)8/10 
Fistulising 30 (9) 24.5 (24) 0.099 
All 35.1  (53) 30.7 (86) 0.186 
Luminal 32.2 (39) 30.2 (55) 0.188 
rs909253 (A/G) 
Fistulising 46.7 (14) 31.6 (31) 0.362 
All 25 (37) 30 (84) 0.202 
Luminal 26.3 (31) 32.4 (59) 0.414 
rs2857713 (A/G) 
Fistulising 20 (6) 25.5 (25) 0.099 
All 35.8 (53) 31.8 (89) 0.421 
Luminal 33 (39) 31.9 (58) 0.297 
rs1041981 (A/C) 
Fistulising 46.7 (14) 31.6 (31) 0.321 
All 37.8 (56) 39.6 (111) 0.370 
Luminal 38.1 (45) 37.4 (68) 0.505 
rs746868 (C/G) 
Fistulising 20 (6) 41.8 (41) 0.026 
All 5.4 (8) 5.7 (16) 0.535 
Luminal 6.8 (8) 6.6 (12) 0.567 
rs3093543 (A/C) 
Fistulising 0(0) 4(4) 0.347 
For each polymorphism, the minor allele frequencies and allele number are noted for each subgroup of patients (complete cohort, luminal or 
fistulising form, n = number of patients) and the clinical response (nonresponders and responders). P-values were obtained after 
comparison of allele frequencies between responders and nonresponders, on all (n=214), luminal (n=150) or fistulising patients (n = 64). 
 
Table 4. LTA 1_1_1_1 halotpype frequencies (%) in responding and nonresponding patients for clinical 
response 
Clinical response Biological response  
Responders Nonresponders P Responders Nonresponders P 
Complete cohort (η) 1 6.9 (20) 10.4 (7) 0.22 3.8 (1) 10.6 (12) 0.40 
Luminal disease (η) 5.2 (9) 5.3 (6) 0.58 5(1) 7(6) 0.78 
Fistulising disease (n) 12.6 (11) 3.4 (1) 0.16 0(0) 22.2 (6) 0.22 
For each subgroup of patients, the frequencies of homozygous patients for the LTA 1_1_1_1 haplotype (respectively rs909253_rs5875327_rs2857713_rs1041 
981, noted 1 for the major allele) and the number of homozygous patients (η) are reported. P-values considering both clinical and biological response were 
obtained after comparison of each haplotype frequency in both groups of responding and nonresponding patients. The clinical response was evaluated on 214 
patients (150 with a luminal disease and 64 with a fistulising disease), whereas 139 patients were evaluated for the biological response (106 with a luminal 
disease and 33 with a fistulising disease). 
Published in: Pharmacogenetics and Genomics (2006), vol. 16, iss. 5, pp. 369-373 
Status : Postprint (Author’s version) 
Discussion 
Genetic factors may be implicated in the response rate to infliximab. Several genes have already been studied to 
associate genetic variation with clinical or biological response to this drug [13]. In the present study, we focused 
on the previously described association between a LTA haplotype and the lack of response to infliximab.  
The LTA gene is localized on the short arm of chromosome 6 within the region of the major histocompatibility 
complex, and this region has been associated with variation in immune response and with predisposition to CD 
[14]. Recent studies have also demonstrated a correlation between this location and the response to infliximab in 
rheumatoid arthritis [6]. Several genes controlling the immune response are located within this region, such as 
the TNF and LTA genes, encoding for two closely related cytokines. Several polymorphisms in the TNF 
promoter have already been studied on large CD cohorts without any evidence for an association between these 
polymorphisms and the response to infliximab [15,16]. However, the LTA 1_1_1_1 haplotype was shown to be 
significantly associated with a lack of response to infliximab [7]. A genetic variation in this region, which would 
be in linkage disequilibrium with the described haplotype, could be suspected to influence the response rate to 
infliximab. The implication of a genetic variation in the LTA gene itself or in the TNF gene is attractive 
considering the role of these cytokines in immunity and inflammation. However, before any further study of this 
genetic region, a confirmation of the implication of the LTA 1_1_1_1 haplotype was required considering the 
small size of the previously studied cohort. 
The present study included 214 Caucasian patients who were treated with infliximab. The response to infliximab 
was evaluated considering both clinical and biological data. We studied the complete cohort as well as the 
luminal or fistulising forms separately. Despite the same clinical classification as used in Taylor's study, we did 
not find any association between the previously described haplotype and the response to infliximab. Considering 
also other criteria of response as fistula discharge for fistulising disease or a biological response based on the 
CRP level, no association was found between response to the drug and the studied LTA haplotype. The studied 
polymorphisms are in linkage disequilibrium with TNF microsatellite haplotypes, consisting of five 
microsatellites which encompass the region, including the LTB, TNF and LTA genes. By extension, the lack of 
association observed in the present study could also be considered for these haplotypes, with a diminution of 
power. Other candidate genes involved in TNF signalling pathways should be studied in reasonably large 
cohorts, with a strict definition of drug response. 
The cohort of Taylor et al. [7] was relatively small and reliable results could not be expected without a larger 
confirmatory cohort. Considering our cohort size, the haplotype frequency and various degrees of influence of 
the LTA haplotype on the treatment response rate, we evaluated the probability of detecting a significant 
association between the haplotype and the response to infliximab. If we consider a decrease in the response rate 
of 20, 40 or 70% (associated with the LTA haplotype), the probability of finding an association with Taylor's 
cohort was, respectively, of 0.094, 0.314 and 0.675. When considering an effect of 40% and the size of our 
cohort, the risk of missing a real association is less than 10% and this drops to less than 1% if the effect is greater 
than 50%. These results suggest that the size of our cohort is sufficient to exclude a response rate reduction of at 
least 40% associated with the LTA 1_1_1_1  haplotype. However, the probability of detecting an effect of 20% 
or less with our cohort falls to 0.346 and the cohort size should be increased to 600 or 1500 patients to exclude a 
potential effect of 20 and 10%, respectively, of this haplotype on the prevalence of response. 
It is likely that the response to infliximab is a multifactorial mechanism involving both environmental and 
genetic factors. The implication of genetic determinants on the response is probably weak. Therefore, 
independent pharmacogenetic studies should carefully evaluate clinical and biological response in large cohorts 
of patients. As very few groups will be able to study such cohorts, large multicenter studies or meta-analysis will 
need to be performed to provide definitive evidence for the presence or absence of any association between the 
LTA haplotypes and infliximab response. Negative and positive studies should thus be reported or collected to 
be included in such meta-analysis. 
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